AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy Sells 12,220 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

AnaptysBio Stock Down 3.2 %

NASDAQ:ANAB traded down $1.22 on Tuesday, reaching $37.50. 340,978 shares of the company’s stock traded hands, compared to its average volume of 329,314. The stock has a 50-day simple moving average of $35.23 and a 200-day simple moving average of $27.63. AnaptysBio, Inc. has a 12 month low of $13.36 and a 12 month high of $41.31. The firm has a market cap of $1.02 billion, a PE ratio of -6.11 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The business had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. On average, equities analysts anticipate that AnaptysBio, Inc. will post -6.84 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on ANAB shares. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a report on Wednesday, August 14th. Truist Financial upped their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Finally, JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.30.

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio in the 1st quarter worth $38,000. Headlands Technologies LLC boosted its stake in AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 66.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 2,051 shares in the last quarter. Quest Partners LLC bought a new stake in AnaptysBio in the 4th quarter worth approximately $119,000. Finally, Virtu Financial LLC purchased a new stake in shares of AnaptysBio during the 1st quarter worth approximately $222,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.